CA
NZ
UK
AU
IND
US
…
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 172.20M | -173.24M | -43.52M | -112.58M | -69.47M |
| Net income | 172.17M | -255.79M | -42.13M | -173.65M | -69.47M |
| Selling general administrative | 22.13M | 18.67M | 13.66M | 21.17M | 23.58M |
| Gross profit | 33.38M | 1.98M | 5.37M | 12.52M | 7.22M |
| Reconciled depreciation | 0.10M | 0.17M | 0.40M | 0.56M | 0.86M |
| Ebit | -60.39M | -173.40M | -44.92M | 13.54M | -72.12M |
| Ebitda | -290.06M | -7.62M | -44.52M | 14.11M | -71.26M |
| Depreciation and amortization | -229.67M | 165.78M | 0.40M | 0.56M | 0.86M |
| Non operating income net other | 229.67M | - | - | - | - |
| Operating income | -60.39M | -173.40M | -44.52M | 13.54M | -71.61M |
| Other operating expenses | 94.21M | 92.49M | 49.89M | 63.46M | 78.82M |
| Interest expense | 2.92M | 165.61M | 0.99M | 0.00M | 2.48M |
| Tax provision | 0.04M | - | - | - | - |
| Interest income | 2.92M | 0.16M | 0.99M | 3.41M | 2.48M |
| Net interest income | 2.92M | 0.16M | 0.99M | 3.41M | 2.48M |
| Non recurring | - | 82.89M | - | 65.05M | - |
| Income tax expense | 0.04M | 82.56M | -1.40M | 61.07M | 2.13M |
| Total revenue | 33.82M | 1.98M | 5.37M | 12.52M | 7.22M |
| Total operating expenses | 93.76M | 92.49M | 49.89M | 63.46M | 78.82M |
| Cost of revenue | 0.45M | - | - | 38.49M | 55.24M |
| Total other income expense net | 232.59M | 0.16M | 0.99M | -126.12M | -0.35M |
| Net income from continuing ops | 172.17M | -173.24M | -43.52M | -112.58M | -69.47M |
| Net income applicable to common shares | 172.17M | -173.24M | -43.52M | -112.58M | -69.47M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 212.77M | 279.34M | 100.54M | 84.72M | 119.38M |
| Other current assets | 5.04M | 9.76M | 4.68M | 2.36M | 3.38M |
| Total liab | 19.75M | 22.48M | 32.29M | 11.35M | 9.42M |
| Total stockholder equity | 193.03M | 256.86M | 68.25M | 73.38M | 109.95M |
| Deferred long term liab | - | 0.30M | - | - | - |
| Other current liab | 14.75M | 17.38M | 13.11M | 7.25M | 6.83M |
| Common stock | 0.09M | 0.09M | 0.09M | 0.06M | 0.06M |
| Capital stock | 0.09M | 0.09M | 0.09M | 0.06M | 0.06M |
| Retained earnings | -795.52M | -713.43M | -885.60M | -712.36M | -668.84M |
| Other liab | - | 0.25M | - | - | - |
| Other assets | - | 0.39M | 0.06M | 2.85M | 0.03M |
| Cash | 27.66M | 25.84M | 15.40M | 46.99M | 16.90M |
| Total current liabilities | 18.44M | 20.41M | 29.90M | 8.53M | 9.23M |
| Net debt | -25.52M | -23.77M | 0.99M | -44.17M | -16.70M |
| Short term debt | 0.84M | - | 14.00M | 4.30M | - |
| Short long term debt | - | - | 14.00M | - | - |
| Short long term debt total | 2.14M | 2.07M | 16.39M | 2.81M | 0.20M |
| Other stockholder equity | 988.46M | 970.53M | 953.78M | 785.67M | 778.69M |
| Property plant equipment | - | 0.23M | 2.66M | 0.21M | 0.54M |
| Total current assets | 189.01M | 228.14M | 95.81M | 81.66M | 118.09M |
| Long term investments | 21.66M | 48.63M | 2.02M | - | - |
| Net tangible assets | - | 256.86M | 68.25M | 73.38M | 109.95M |
| Short term investments | 155.17M | 191.49M | 72.97M | 31.97M | 96.57M |
| Net receivables | 1.14M | 1.04M | 0.35M | 0.34M | 1.23M |
| Long term debt | 0.12M | 0.25M | - | - | - |
| Inventory | - | 0.00M | 2.76M | - | - |
| Accounts payable | 2.85M | 3.03M | 2.79M | 1.28M | 2.40M |
| Accumulated other comprehensive income | 0.01M | -0.34M | -0.02M | - | 0.04M |
| Common stock total equity | - | 0.09M | 0.09M | 0.06M | 0.06M |
| Retained earnings total equity | - | -713.43M | -885.60M | -712.36M | -668.84M |
| Non currrent assets other | 0.40M | 0.39M | 0.06M | 0.03M | 0.03M |
| Non current assets total | 23.76M | 51.20M | 4.74M | 3.06M | 1.28M |
| Capital lease obligations | 1.18M | 1.82M | 2.39M | 2.81M | 0.20M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -163.88M | -43.88M | 64.76M | 10.79M | 105.28M |
| Change to liabilities | 5.50M | 7.06M | -0.19M | -4.29M | 0.01M |
| Total cashflows from investing activities | 70.04M | -44.09M | 64.71M | 10.63M | 105.09M |
| Net borrowings | -14.00M | -14.00M | -14.00M | -14.00M | - |
| Total cash from financing activities | -12.72M | 112.43M | 1.41M | 0.34M | 11.19M |
| Change to operating activities | -5.42M | -2.35M | 1.02M | -0.78M | 0.64M |
| Net income | 172.17M | -173.24M | -43.52M | -112.58M | -69.47M |
| Change in cash | 10.45M | -31.59M | 30.09M | -64.20M | 62.56M |
| Begin period cash flow | 15.40M | 46.99M | 16.90M | 81.11M | 18.55M |
| End period cash flow | 25.84M | 15.40M | 46.99M | 16.90M | 81.11M |
| Total cash from operating activities | -46.87M | -99.93M | -36.04M | -75.18M | -53.73M |
| Issuance of capital stock | 0.00M | 107.84M | 0.00M | - | 10.87M |
| Depreciation | 0.10M | 0.17M | 0.40M | 0.56M | 0.86M |
| Other cashflows from investing activities | 233.98M | - | 0.01M | 10.79M | 105.28M |
| Change to inventory | -2.47M | -2.76M | 0.19M | 4.29M | -0.01M |
| Change to account receivables | -1.04M | 0.34M | 0.89M | -0.90M | 1.35M |
| Sale purchase of stock | 1.27M | 112.43M | 1.41M | 0.34M | 11.19M |
| Other cashflows from financing activities | 0.67M | 4.59M | 1.41M | -34.55M | 0.32M |
| Change to netincome | -214.39M | 12.26M | 5.55M | 44.72M | 13.45M |
| Capital expenditures | 0.07M | 0.21M | 0.06M | 0.16M | 0.18M |
| Change receivables | -1.04M | 0.34M | 0.89M | -0.90M | 1.35M |
| Cash flows other operating | -5.41M | 55.39M | 1.01M | -0.85M | 0.93M |
| Cash and cash equivalents changes | 10.45M | -31.59M | 30.09M | -64.20M | 62.56M |
| Change in working capital | -3.42M | 2.29M | 1.73M | -5.97M | 2.00M |
| Stock based compensation | 15.29M | 12.26M | 5.57M | 9.53M | 13.07M |
| Other non cash items | -231.00M | 57.75M | -0.01M | 34.82M | -0.06M |
| Free cash flow | -46.94M | -100.14M | -36.10M | -75.34M | -53.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.21 0.54% |
38.92 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
6.94 0.86% |
814.61 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael A. Sherman M.B.A. | CEO, Pres & Director | 1966 |
| Mr. Michael T. Andriole M.B.A. | Chief Bus. Officer, Sec. & CFO | 1973 |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer | 1964 |
| Mr. David Jakeman CPA | Exec. Director of Fin. & Accounting and Principal Accounting Officer | 1978 |
| Dr. Roy W. Ware | Chief Manufacturing & Technology Officer | NA |
| Dr. Randall Lanier | Chief Science Officer | NA |
| Ms. Michelle LaSpaluto | VP of Strategic Planning & Investor Relations | NA |
| Dr. Michael A. Alrutz | Sr. VP, Gen. Counsel & Corp. Sec. | 1970 |
| Dr. Joshua E. Allen | Chief Technology Officer of Imipridones | NA |
| Mr. Michael T. Andriole M.B.A. | CEO, President & Director | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...